The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Updates from ASH in CLL therapy: big trials, big results
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, shares an overview of key updates in treatment for chronic lymphocytic leukemia (CLL), including the MURANO (NCT02005471), iLLUMINATE (NCT02264574), ALLIANCE A041202 (NCT01886872), and ECOG-E1912 (NCT02048813) studies, aiming to uncover the most effective initial therapy for CLL. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Hillmen describes the superiority of frontline targeted treatments compared with chemotherapy.
